Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of amikacin in cystic fibrosis patients with nontuberculous mycobacterial infections

X
Trial Profile

Phase II study of amikacin in cystic fibrosis patients with nontuberculous mycobacterial infections

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amikacin (Primary)
  • Indications Nontuberculous mycobacterium infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Oct 2021 According to an Matinas BioPharma Media release, the company expects to initiate this study by the first quarter of 2023, following required longer-term preclinical toxicology studies to be conducted during 2022.
    • 10 May 2021 According to an Matinas BioPharma Media release, the company expects to initiate this trial in 2022.
    • 20 Dec 2020 According to a Matinas BioPharma media release, the Cystic Fibrosis Foundation (CFF) has indicated to the company a willingness to consider a request for monetary support for the continuation of clinical studies, including dose determination and Phase 2 efficacy studies in CF patients suffering from NTM lung disease.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top